Investigation on Ataxin2 and Matrin3 in neurodegenerative disease

Ataxin2 和 Matrin3 在神经退行性疾病中的研究

基本信息

  • 批准号:
    10668022
  • 负责人:
  • 金额:
    $ 42.21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-04-01 至 2025-03-31
  • 项目状态:
    未结题

项目摘要

Dysfunction or mutation of RNA binding proteins (RBPs) is associated with a growing number of neurodegenerative diseases (NDDs), including amyotrophic lateral sclerosis (ALS), AD/ADRDs and spinocerebellar ataxia type 2 (SCA2). The RBP Ataxin-2 is a potent modifier of ALS and targeting therapeutics are already in clinical trials. However, the underlying pathogenic mechanisms of Ataxin-2 in ALS and dementias, and the roles of its interaction with other pathogenic RBPs are poorly understood. We found that the nuclear matrix RBP Matrin-3 interacts with Ataxin-2 and propose to study the interaction functionally in ALS/FTD-relevant neurons. Mutations in Matrin-3 cause FTD, familial ALS and multisystem proteinopathy (MSP). Like TDP-43, Matrin-3 proteinopathy has been observed in ALS/FTD even when it is not mutated. Cytoplasmic aggregation of Matrin-3 has also been observed in Alzheimer’s disease (AD) patient neurons. Our preliminary data suggest that targeting MATR3 may be therapeutic for these disorders: We observed Matrin-3 overabundance in fibroblasts from ALS and FTD patients with C9ORF72 and TDP-43 mutations, that was normalized by lowering ATXN2 expression by RNAi. The FTD/ALS-relevant Matrin3-S85C mouse model displays extensive selective Purkinje cell (PC) loss. PCs are the neurons affected in SCA2 and the neuronal population with the greatest susceptibility to Ataxin-2 mutations. The severe cerebellar neurodegeneration in Matrin-3 S85C mice suggests a pathological link between Matrin-3 and Ataxin-2 that could define a neuronal death pathway relevant to other NDDs including FTD. We propose that in the context of disease, Ataxin-2 interaction with Matrin-3 will contribute to the development of pathology, and that targeting Ataxin-2 will mitigate Matrin-3 pathology and neuronal death. We plan to study pathology linked to Ataxin-2, Matrin-3 and ALS in isolated cultured neurons derived from Ataxin-2 knockout, Ataxin-2 expansion and TDP-43 mutation mice. We will determine the contribution of the different RBPs by expressing Matrin-3 mutations and/or knocking down Ataxin-2 with adenovirus and antisense oligonucleotide strategies already developed. The pathological phenotypes we propose to study include Matrin-3 levels, localization, changes in solubility, aggregation into condensates and toxicity to neurons, as well as ALS molecular readouts including TDP-43 aggregation and localization. We will also investigate the nucleation of other relevant proteinopathy biomolecules into the condensates. Analyzing these in the context of normal, expanded and knockout Ataxin-2 and mutated TDP-43 will inform on the roles of Ataxin-2, Matrin-3 and the interplay of RBPs in the pathogenetic mechanisms in SCA2 and ALS/FTD. This study will provide the initial proof-of-concept for directly targeting ATXN2 and MATR3 in ALS and FTD patients with MATR3 mutations, as well as in other AD/ADRD patients with Matrin-3 proteinopathy.
RNA结合蛋白(RBP)的功能障碍或突变与越来越多的 神经退行性疾病(NDD),包括肌萎缩侧索硬化(ALS)、AD/ADRD和脊髓小脑共济失调2型(SCA 2)。RBP Ataxin-2是ALS的有效调节剂,靶向治疗已经在临床试验中。然而,Ataxin-2在ALS和痴呆中的潜在致病机制及其与其他致病RBP相互作用的作用知之甚少。我们发现核基质RBP Matrin-3与Ataxin-2相互作用,并建议在ALS/FTD相关神经元中研究功能上的相互作用。Matrin-3突变导致FTD、家族性ALS和多系统蛋白病 (MSP)。与TDP-43一样,Matrin-3蛋白质病在ALS/FTD中观察到,即使它没有突变。在阿尔茨海默病(AD)患者神经元中也观察到Matrin-3的细胞质聚集。我们的初步数据表明,靶向MATR 3可能对这些疾病有治疗作用:我们观察到,在ALS和FTD患者的成纤维细胞中,Matrin-3过量,这些患者具有C9 ORF 72和TDP-43突变,通过RNAi降低ATXN 2表达使其正常化。FTD/ALS相关Matrin 3-S85 C小鼠模型显示广泛的选择性浦肯野细胞(PC)损失。PC是SCA 2中受影响的神经元, 对Ataxin-2突变最敏感的人群。Matrin-3 S85 C小鼠中的重度小脑神经变性表明Matrin-3和共济失调蛋白-2之间存在病理学联系,可定义与其他NDD(包括FTD)相关的神经元死亡途径。我们提出,在疾病的背景下,Ataxin-2与Matrin-3的相互作用将有助于病理学的发展,并且靶向Ataxin-2将减轻Matrin-3病理学和神经元死亡。我们计划在分离的培养神经元中研究与Ataxin-2,Matrin-3和ALS相关的病理学,这些神经元来自Ataxin-2敲除,Ataxin-2扩增和TDP-43突变 小鼠我们将通过表达Matrin-3突变和/或用腺病毒和已经开发的反义寡核苷酸策略敲低Ataxin-2来确定不同RBP的贡献。我们建议研究的病理表型包括Matrin-3水平、定位、溶解度变化、聚集成凝聚物和对神经元的毒性,以及ALS分子读数,包括TDP-43聚集和定位。我们还将研究其他相关蛋白质病生物分子成核到冷凝物中。在正常、扩增和敲除Ataxin-2和突变的TDP-43的背景下分析这些将告知Ataxin-2、Matrin-3的作用以及RBP在SCA 2和ALS/FTD的发病机制中的相互作用。本研究将为直接靶向ATXN 2和MATR 3治疗伴有MATR 3突变的ALS和FTD患者以及伴有Matrin-3蛋白病的其他AD/ADRD患者提供初步概念验证。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mariana Mandi Gandelman其他文献

Mariana Mandi Gandelman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Whole Genome Sequencing to identify novel loci in French Canadian ALS patients
全基因组测序识别法裔加拿大 ALS 患者的新基因座
  • 批准号:
    387259
  • 财政年份:
    2017
  • 资助金额:
    $ 42.21万
  • 项目类别:
    Studentship Programs
Elucidation of the optimal period of PAP therapy aiming at oral ingestion by ALS patients.
阐明针对 ALS 患者口服摄入的 PAP 治疗的最佳时期。
  • 批准号:
    19K20753
  • 财政年份:
    2016
  • 资助金额:
    $ 42.21万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
The effect of TNF-alpha on microglial induced hyperexcitation in cortical neurons of ALS patients
TNF-α对ALS患者皮质神经元小胶质细胞过度兴奋的影响
  • 批准号:
    367192
  • 财政年份:
    2016
  • 资助金额:
    $ 42.21万
  • 项目类别:
    Studentship Programs
Study of a communication support system for ALS patients based on changes in cerebral ongoing activity
基于大脑持续活动变化的ALS患者沟通支持系统研究
  • 批准号:
    15K12605
  • 财政年份:
    2015
  • 资助金额:
    $ 42.21万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Comprehensive genetic analysis of ALS-related genes in Japanese sporadic ALS patients
日本散发性ALS患者ALS相关基因综合遗传分析
  • 批准号:
    15K19485
  • 财政年份:
    2015
  • 资助金额:
    $ 42.21万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
ALS4 mice show TDP-43 protein mislocalization in motor neurons characteristic of sporadic ALS patients; suggesting this model is likely to reveal important patho-mechanistic disease insights
ALS4 小鼠在运动神经元中显示 TDP-43 蛋白错误定位,这是散发性 ALS 患者的特征;
  • 批准号:
    nhmrc : 1045520
  • 财政年份:
    2013
  • 资助金额:
    $ 42.21万
  • 项目类别:
    NHMRC Project Grants
Study of restoration process of the living environments of bereaved families that had undertaken long-term at-home care for ALS patients
长期居家护理ALS患者家属生活环境恢复过程研究
  • 批准号:
    24760510
  • 财政年份:
    2012
  • 资助金额:
    $ 42.21万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Microarray analysis in spinal cords of sporadic ALS patients with cell-type specific transcriptome
散发性 ALS 患者脊髓中细胞类型特异性转录组的微阵列分析
  • 批准号:
    24591259
  • 财政年份:
    2012
  • 资助金额:
    $ 42.21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A pathological study of impaired cytoplasmic-nuclear transport impairment infamilial ALS patients harboring FUS mutatio
携带FUS突变的家族性ALS患者细胞质-核转运受损的病理学研究
  • 批准号:
    23790997
  • 财政年份:
    2011
  • 资助金额:
    $ 42.21万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
MODEL FOR THE PROMOTION OF A BARRIER-FREE MIND IN THE FAMILY CAREGIVER OF ALS PATIENTS
促进 ALS 患者家庭护理人员无障碍心态的模型
  • 批准号:
    23593266
  • 财政年份:
    2011
  • 资助金额:
    $ 42.21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了